Evidence map›Paper›PMID 33333700›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2020

[allo-CD19-CAR-T cells therapy followed with same-donor allo-HSCT to treat relapsed B-ALL: two cases report and literatures review].

N N Li, L H Liu, J F Yang, L J Fan, X X Gao, D X Yin, P H Lu, J P Zhang

Open access · greenAbstract readCase Reports
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

N N LiDepartment of BMT, Hebei Yanda Lu Daopei Hospital, Langfang 065201, China.
L H LiuDepartment of BMT, Hebei Yanda Lu Daopei Hospital, Langfang 065201, China.
J F YangDepartment of Hematology, Hebei Yanda Lu Daopei Hospital, Langfang 065201, China.
L J FanDepartment of BMT, Hebei Yanda Lu Daopei Hospital, Langfang 065201, China.
X X GaoDepartment of BMT, Hebei Yanda Lu Daopei Hospital, Langfang 065201, China.
D X YinDepartment of BMT, Hebei Yanda Lu Daopei Hospital, Langfang 065201, China.
P H LuDepartment of Hematology, Hebei Yanda Lu Daopei Hospital, Langfang 065201, China.
J P ZhangDepartment of BMT, Hebei Yanda Lu Daopei Hospital, Langfang 065201, China.
Luye Pharma (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hematopoietic Stem Cell TransplantationImmunotherapy, AdoptiveNeoplasm Recurrence, LocalAntigens, CD19HumansPrecursor Cell Lymphoblastic Leukemia-LymphomaT-LymphocytesAntigens, CD19

Identifiers

PMID33333700
PMCPMC7767802
OpenAlexW3115244891

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.